<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37024626</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0973</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Infection</Title><ISOAbbreviation>Infection</ISOAbbreviation></Journal><ArticleTitle>The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study.</ArticleTitle><Pagination><StartPage>1633</StartPage><EndPage>1644</EndPage><MedlinePgn>1633-1644</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15010-023-02028-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Oral antivirals (nirmatrelvir/ritonavir and molnupiravir), intravenous short treatment of remdesivir and anti-SARS-CoV-2 monoclonal antibodies (mAbs) have been used for early COVID-19 treatments in high risk of disease progression patients. The term long COVID has been used to refer to a range of new, returning, or ongoing symptoms after SARS-CoV-2 infection. Little is known about the impact of such therapies on long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective observational study, including all outpatients evaluated from April 2021 to March 2022 in Brescia, Lombardy, northern Italy. Patients were stratified in three groups: (a) treated with mAbs, (b) treated with antivirals drugs and (c) controls (patients eligible for a or b who refused treatment). Data were collected at baseline and at month 1 and 3 (data on self-reported symptoms were collected using a telephone-administered questionnaire). We assessed early COVID-19 therapies effectiveness in preventing hospitalization, death at 1 or 3&#xa0;months and persisting symptoms at 3&#xa0;months after the onset of SARS-CoV-2 infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 649 patients were included in the study, of which 242 (37.3%) were treated with mAbs, 197 (30.3%) with antiviral drugs and 210 (32.4%) were not treated. Patients most frequently reported cerebro-cardiovascular diseases (36.7%) followed by obesity (22%). Overall, 29 patients (4.5%) died or were hospitalized at 1 or 3-month follow-up. Death or hospitalization was positively associated with older ages, with a significant linear trend (OR 3.05; 95% CI 1.16-8.06, for patients aged 80 or more years compared to those aged less than 65). Data on long COVID at 3&#xa0;months were available for 323 (49.8%) patients. A positive association emerged for females compared to men, with an OR of 2.14 (95% CI 1.30-3.53) for any symptoms. Conversely, inverse associations were found for treatment groups as compared to the control one, with significant estimates among patients treated with antiviral drugs for any symptoms (OR 0.43, 95% CI 0.21-0.87) and patients treated with mAbs for any neuro-behavioral symptoms (OR 0.48, 95% CI 0.25-0.92).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We report beneficial effect of early use of anti-SARS-CoV-2 antivirals and mAbs on long COVID.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertuccio</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Degli Antoni</LastName><ForeName>Melania</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili Di Brescia and University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minisci</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili Di Brescia and University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amadasi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili Di Brescia and University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castelli</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili Di Brescia and University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odone</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quiros-Roldan</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili Di Brescia and University of Brescia, Brescia, Italy. eugeniaquiros@yahoo.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Infection</MedlineTA><NlmUniqueID>0365307</NlmUniqueID><ISSNLinking>0300-8126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antivirals</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Early COVID-19 therapies</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">PCC</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>6</Day><Hour>23</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37024626</ArticleId><ArticleId IdType="pmc">PMC10079146</ArticleId><ArticleId IdType="doi">10.1007/s15010-023-02028-5</ArticleId><ArticleId IdType="pii">10.1007/s15010-023-02028-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J. 2021;23:14. doi: 10.1208/s12248-020-00532-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-020-00532-2</ArticleId><ArticleId IdType="pmc">PMC7784226</ArticleId><ArticleId IdType="pubmed">33400058</ArticleId></ArticleIdList></Reference><Reference><Citation>Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19) Postgrad Med J. 2020;96:753&#x2013;758. doi: 10.1136/postgradmedj-2020-138234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-138234</ArticleId><ArticleId IdType="pmc">PMC10016932</ArticleId><ArticleId IdType="pubmed">32563999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13:1833&#x2013;1839. doi: 10.1016/j.jiph.2020.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.07.014</ArticleId><ArticleId IdType="pmc">PMC7402107</ArticleId><ArticleId IdType="pubmed">32788073</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2:1069&#x2013;1076. doi: 10.1007/s42399-020-00363-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-020-00363-4</ArticleId><ArticleId IdType="pmc">PMC7314621</ArticleId><ArticleId IdType="pubmed">32838147</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553&#x2013;556. doi: 10.1038/s41586-022-04594-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04594-4</ArticleId><ArticleId IdType="pmc">PMC9021018</ArticleId><ArticleId IdType="pubmed">35240676</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate covid-19. N Engl J Med. 2021;385:1382&#x2013;1392. doi: 10.1056/NEJMoa2102685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102685</ArticleId><ArticleId IdType="pmc">PMC8314785</ArticleId><ArticleId IdType="pubmed">34260849</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021;384:238&#x2013;251. doi: 10.1056/NEJMoa2035002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035002</ArticleId><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327:1236&#x2013;1246. doi: 10.1001/jama.2022.2832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.2832</ArticleId><ArticleId IdType="pmc">PMC8922199</ArticleId><ArticleId IdType="pubmed">35285853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2022;386:305&#x2013;315. doi: 10.1056/NEJMoa2116846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Uso degli anticorpi monoclonali per COVID-19&#x2014;Agenzia Italiana del Farmaco. https://www.aifa.gov.it/uso-degli-anticorpi-monoclonali. Accessed 10 Jan 2023</Citation></Reference><Reference><Citation>Uso degli antivirali per COVID-19&#x2014;Agenzia Italiana del Farmaco. https://www.aifa.gov.it/uso-degli-antivirali-orali-per.covid-19. Accessed 10 Jan 2023</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Post-COVID conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed 10 Jan 2023</Citation></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473&#x2013;1487. doi: 10.1080/07853890.2022.2076901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gennaro F, Belati A, Tulone O, et al. Incidence of long COVID-19 in people with previous SARS-Cov2 infection: a systematic review and meta-analysis of 120,970 patients. Intern Emerg Med. 2022;30:1&#x2013;9. doi: 10.1007/s11739-022-03164-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-022-03164-w</ArticleId><ArticleId IdType="pmc">PMC9709360</ArticleId><ArticleId IdType="pubmed">36449260</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-months consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022;328:676&#x2013;678. doi: 10.1001/jama.2022.11691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi RT, Lynch JB, Del Rio C. Mild or moderate covid-19. N Engl J Med. 2020;383:1757&#x2013;1766. doi: 10.1056/NEJMcp2009249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2009249</ArticleId><ArticleId IdType="pubmed">32329974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID-19: virology, biology and novel laboratory diagnosis. J Gene Med. 2021;23:e3303. doi: 10.1002/jgm.3303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgm.3303</ArticleId><ArticleId IdType="pmc">PMC7883242</ArticleId><ArticleId IdType="pubmed">33305456</ArticleId></ArticleIdList></Reference><Reference><Citation>Istituto superiore di sanit&#xe0;. Speciale COVID-19&#x2014;varianti del virus. https://www.iss.it/cov19-cosa-fa-iss-varianti. Accessed 10 Jan 2023</Citation></Reference><Reference><Citation>Sullivan DJ, Gebo KA, Shoham S, et al. Early outpatient treatment for covid-19 with convalescent plasma. N Engl J Med. 2022;386:1700&#x2013;1711. doi: 10.1056/NEJMoa2119657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119657</ArticleId><ArticleId IdType="pmc">PMC9006786</ArticleId><ArticleId IdType="pubmed">35353960</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R, P&#xe9;rez Marc G, Wappner D, et al. Early high-Titer plasma therapy to prevent severe covid-19 in older adults. N Engl J Med. 2021;384:610&#x2013;618. doi: 10.1056/NEJMoa2033700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2033700</ArticleId><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with covid-19. N Engl J Med. 2021;385:1951&#x2013;1960. doi: 10.1056/NEJMoa2103784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103784</ArticleId><ArticleId IdType="pmc">PMC8385553</ArticleId><ArticleId IdType="pubmed">34407339</ArticleId></ArticleIdList></Reference><Reference><Citation>Daitch V, Yelin D, Awwad M, et al. Characteristics of long COVID among older adults: a cross-sectional study. Int J Infect Dis. 2022 doi: 10.1016/j.ijid.2022.09.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.09.035</ArticleId><ArticleId IdType="pubmed">36191820</ArticleId></ArticleIdList></Reference><Reference><Citation>Odone A, Delmonte D, Scognamiglio T, et al. COVID-19 deaths in Lombardy, Italy: data in context. Lancet Public Health. 2020;5:e310. doi: 10.1016/S2468-2667(20)30099-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30099-2</ArticleId><ArticleId IdType="pmc">PMC7182509</ArticleId><ArticleId IdType="pubmed">32339478</ArticleId></ArticleIdList></Reference><Reference><Citation>Maifredi G, Izzo I, Gasparotti C, et al. SARS-CoV-2 infection and vaccination coverage among fragile populations in a local health area of Northern Italy. Life (Basel) 2022;12:1009. doi: 10.3390/life12071009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12071009</ArticleId><ArticleId IdType="pmc">PMC9316873</ArticleId><ArticleId IdType="pubmed">35888096</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmani S, Rezaei N. SARS-CoV-2 Omicron variant: why global communities should take it seriously? Immun Inflamm Dis. 2022;10:e618. doi: 10.1002/iid3.618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.618</ArticleId><ArticleId IdType="pmc">PMC9017627</ArticleId><ArticleId IdType="pubmed">35478443</ArticleId></ArticleIdList></Reference><Reference><Citation>Esper FP, Adhikari TM, Tu ZJ, et al. Alpha to omicron: disease severity and clinical outcomes of major SARS-CoV-2 variants. J Infect Dis. 2022 doi: 10.1093/infdis/jiac411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac411</ArticleId><ArticleId IdType="pmc">PMC9619650</ArticleId><ArticleId IdType="pubmed">36214810</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosato M, Carf&#xec; A, Martis I, et al. Prevalence and predictors of persistence of COVID-19 symptoms in older adults: a single-center study. J Am Med Dir Assoc. 2021;22:1840&#x2013;1844. doi: 10.1016/j.jamda.2021.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2021.07.003</ArticleId><ArticleId IdType="pmc">PMC8286874</ArticleId><ArticleId IdType="pubmed">34352201</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer RR, Rock MA, Vasilevsky N, et al. Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine. 2021;74:103722. doi: 10.1016/j.ebiom.2021.103722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103722</ArticleId><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O, Merino E, Leon-Ramirez JM, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82:378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Usuga D, Perrin PB, Bogdanova Y, et al. Moderate, little, or no improvements in neurobehavioral symptoms among individuals with long COVID: a 34-country retrospective study. Int J Environ Res Public Health. 2022;19:12593. doi: 10.3390/ijerph191912593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191912593</ArticleId><ArticleId IdType="pmc">PMC9564784</ArticleId><ArticleId IdType="pubmed">36231893</ArticleId></ArticleIdList></Reference><Reference><Citation>Amorim CEN, Gomes VLT, Cristelli MP, et al. High prevalence of long-COVID among kidney transplant recipients: a longitudinal cohort study. Transplantation. 2022 doi: 10.1097/TP.0000000000004359.10.1097/TP.0000000000004359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004359.10.1097/TP.0000000000004359</ArticleId><ArticleId IdType="pmc">PMC9696768</ArticleId><ArticleId IdType="pubmed">36228200</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A, et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun. 2022;13:5663. doi: 10.1038/s41467-022-33415-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33415-5</ArticleId><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Author correction: unexplained post-acute infection syndromes. Nat Med. 2022;28:1723. doi: 10.1038/s41591-022-01952-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01952-7</ArticleId><ArticleId IdType="pubmed">35859204</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122&#x2013;1127. doi: 10.1126/science.abm8108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X, Cao S, Lee AS, et al. Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndrome. JCI Insight. 2022;7:e156713. doi: 10.1172/jci.insight.156713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.156713</ArticleId><ArticleId IdType="pmc">PMC9310538</ArticleId><ArticleId IdType="pubmed">35801588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, et al. Persistent symptoms in adult patients 1 Year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. 2022;74:1191&#x2013;1198. doi: 10.1093/cid/ciab611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. The protective effect of coronavirus disease 2019 (COVID-19) vaccination on postacute sequelae of COVID-19: a multicenter study from a large national health research network. Open Forum Infect Dis. 2022;9:228. doi: 10.1093/ofid/ofac228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac228</ArticleId><ArticleId IdType="pmc">PMC9129153</ArticleId><ArticleId IdType="pubmed">35818362</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannock MD, Chew RF, Preiss AJ, et al. Long COVID risk and pre-COVID vaccination: an EHR-based cohort study from the RECOVER program. medRxiv. 2022 doi: 10.1101/2022.10.06.22280795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.06.22280795</ArticleId><ArticleId IdType="pmc">PMC10201472</ArticleId><ArticleId IdType="pubmed">37217471</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevalainen OPO, Horstia S, Laakkonen S, et al. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat Commun. 2022;13:6152. doi: 10.1038/s41467-022-33825-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33825-5</ArticleId><ArticleId IdType="pmc">PMC9579198</ArticleId><ArticleId IdType="pubmed">36257950</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh D, Lim JCT, Ferna&#xed;ndez SB, et al. Corrigendum: case report: persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID. Front Immunol. 2022;13:1036894. doi: 10.3389/fimmu.2022.1036894.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1036894</ArticleId><ArticleId IdType="pmc">PMC9583834</ArticleId><ArticleId IdType="pubmed">36275692</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghagoli G, Gallo Marin B, Katchur NJ, Chaves-Sell F, Asaad WF, Murphy SA. Neurological involvement in COVID-19 and potential mechanisms: a review. Neurocrit Care. 2021;34:1062&#x2013;1071. doi: 10.1007/s12028-020-01049-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12028-020-01049-4</ArticleId><ArticleId IdType="pmc">PMC7358290</ArticleId><ArticleId IdType="pubmed">32661794</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697&#x2013;707. doi: 10.1038/s41586-022-04569-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>